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Late-breaking clinical trials, Vascular Annual
Meeting, Denver, Colorado, June 11-14, 2009LB1. Two-Year Comparison of Endovascular and Open
Repair of Abdominal Aortic Aneurysm. Lederle FA,
Freischlag JA, Kyriakides TC, Padberg FT Jr, Matsumura
JS, Kohler TR, et al; for the Open Versus Endovascular
Repair (OVER) Veterans Affairs Cooperative Study Group.
Objective: Whether endovascular repair of abdominal
aortic aneurysm (AAA) reduces midterm morbidity and
mortality compared with traditional open repair remains
unclear.
Methods: Eligible patients had AAA for which repair
was planned and that had (1) a maximum diameter of at
least 5.0 cm, or (2) a maximum diameter of at least 4.5 cm
plus rapid enlargement or saccular morphology, or (3) an
associated iliac aneurysm 3.0 cm. Patients had to have
completed all preoperative evaluations, be a candidate for
both procedures, and meet the manufacturer’s indications
for the endovascular system that might be used. Patients
were randomized to endovascular repair with any Food and
Drug Administration-approved system or to open repair
and monitored for up to 2 years. The primary outcome was
all-cause mortality. Secondary outcomes included (1) pro-
cedure failure (failure to complete the repair, additional
aortoiliac procedures, unplanned procedures 30 days,
and secondary therapeutic procedures), (2) days in hospital
and intensive care units, (3) major morbidity at 1 year, and
(4) health-related quality of life. Aneurysm-related mortal-
ity was not a prespecified outcome but will be presented for
comparison with other trials.
Results: Between October 2002 and April 2007, 881
patients were randomized at 42 Veterans Affairs medical
centers. Randomized patients had a mean age of 70, 99%
were men, and 43% had an AAA 5.5 cm. Vital status was
available on all patients. Outcome data will be presented in
2 years.
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doi:10.1016/j.jvs.2009.06.008Commentary LB1: At the time of oral presentation,
the trial investigators reported that 95% of enrolled patients
(99.3% male) received their assigned repair within a mean
of 3 weeks after randomization.
Total mortality in this 2-year analysis did not differ
between endovascular and open groups (7% vs 9.4%, P 
.19). However, endovascular repair had an early survival
advantage: 30-day mortality was significantly lower com-
pared with open repair (0.2% vs 2.3%, P .006), with both
rates lower than previously reported by Comparison of
Endovascular Aneurysm Repair with Open Repair in Pa-
tients with Abdominal Aortic Aneurysm (EVAR-1) and
Dutch Randomised Endovascular Aneurysm Management
(DREAM) investigators. Secondary procedures were more
common after endovascular repair, but the investigators did
not observe an increased late mortality after endovascular
repair by the 2-year follow-up. There was no difference in
quality of life indices. The study is scheduled to end in 2011
and the investigators caution that longer-term follow-up is
necessary to more fully compare the two treatments.
LB2. Interim Report on the Zilver® PTX™ Clinical
Study. Dake MD; for the Zilver® PTX™ Investigators.
Objectives: The Zilver® PTX™ Drug-Eluting Periph-
eral Stent (DES) is undergoing clinical study to evaluate its
potential for improving the treatment of femoropopliteal
artery disease. The clinical study includes 1000 patients
treated with the DES. Approximately 240 DES patients
were enrolled in the randomized arm of the study, and 760
DES patients were enrolled in the registry arm of the study.
Enrollment is complete, and this is an interim report of
registry outcomes, including 2-year follow-up results.
Methods: The Zilver® PTX™ Registry is a prospec-
tive, multicenter, single-arm study with relatively broad
inclusion criteria (eg, no maximum lesion length, de novo
or restenotic lesions, including in-stent restenosis). The
end points include event-free survival (EFS) and freedom
from target lesion revascularization (TLR). Imaging fol-
low-up includes duplex ultrasound imaging and stent ra-
diographs at 6 and 12 months.
Results: This interim analysis includes 6-, 12-, and
24-month data from 742 patients (843 lesions), 592 pa-
tients (673 lesions), and 177 patients (221 lesions), respec-
tively. The corresponding EFS rates were 95%, 87%, and
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82%. Evaluation of stent radiographs is ongoing and cur-
rently suggests fractures in approximately 1.4% (21 of
1486) of stents at 6 months and 1.8% (21 of 1198) at 12
months. Clinical measures (ankle-brachial index, Ruther-
ford score, walking distance, and speed scores) showed
significant improvement, which was maintained through
24 months.
Conclusions: Interim results from the registry, in-
cluding 2-year follow-up, indicate no safety concerns, low
fracture rates, high rates of EFS and freedom from TLR,
and clinical improvement with the DES. Ongoing registry
follow-up, as well as the randomized study, will continue to
evaluate the performance of the Zilver® PTX™ Drug-
Eluting Stent.
Commentary LB2: The investigators report interim
nonrandomized registry data describing the use of drug-
eluting stents in femoropopliteal disease. Generally favor-
able rates of event-free survival, freedom from target lesion
revascularization, and clinical improvement are achieved.
As with all registries, the absence of comparative groups
limits the strength of any conclusions. Information from
the randomized trial is pending. Most participants were
limited to 1-year follow-up, and questions remain about
how this relates to the duration of localized drug delivery
with these drug-eluting stents. How long will any drug
delivery effect be expected to last?
This area continues to be explored, and the perfor-
mance of these stents needs to be compared with other
interventions, including nondrug-eluting stents, and an
exercise/medical therapy approach. Until then, the role
and benefit of drug-eluting stents in peripheral artery dis-
ease remains unclear.
LB3. Five-Year Outcomes of the Medtronic Talent
AAA Stent-Graft Pivotal IDE Trial. Sanchez LA; for
the Talent eLPS IDE Trial Investigators.
Objectives: The Talent Enhanced Low Profile (eLPS)
Trial led to the approval of the Talent abdominal aortic
aneurysm (AAA) stent graft in the United States (US). The
objective was to demonstrate the acute and long-term
safety and effectiveness of endovascular aneurysm repair
(EVAR) using the Talent graft. At 1 year, stent graft
outcomes were compared with open surgery historical con-
trols from the Society of Vascular Surgery (SVS) Lifeline
IDE (investigational device exemption) Registry.
Methods: Between February 2002 and April 2003,
166 patients (91.6% men; mean age, 74.1 years) received
the Talent graft at 13 US centers. Inclusion criteria in-
cluded an AAA 4.0 cm in diameter and a proximal neck
length of 5 mm with a diameter of 14 mm and 32
mm. Postprocedural evaluation involved plain x-ray films
and computed tomography angiography before discharge,
at 30 days, 1 year, and yearly to 5 years. Data from the SVS
open repair IDE registry contained comparable data for
243 patients (81.5% men; mean age, 70.1 years) out to 1
year. Aneurysm-related mortality (ARM) was defined as
death that occurred 1 month of the index procedure totreat the AAA, from AAA rupture, or from any procedure
intended to treat the AAA.
Results: The EVAR population was older and sicker
than the open repair population, with higher rates of ar-
rhythmia (44.0% vs 11.5%), congestive heart failure (28.3%
vs 4.9%), hypertension (83.7% vs 66.7%), and peripheral
vascular disease (46.4% vs 15.6%). EVAR was superior to
open repair for all periprocedural outcomes: mean proce-
dure duration (167.3 vs 196.4 minutes, P .001), blood
transfusion (18.2% vs 56.8%, P .001), median intensive
care unit stay (19.3 vs 74.3 hours, P .001), and mean
hospital stay (3.6 vs 8.2 days, P .001). Freedom from
major adverse events was better for EVAR at 30 days
(89.2% vs 44.0%, P  .001) and 1 year (81.3% vs 42.4%, P
 .001). Freedom from ARM was superior for EVAR at 1
year (98.2% vs 96.7%) and was 96.5% for EVAR at 5 years.
Freedom from aneurysm rupture was 98.2%, and conver-
sion to surgery was 99.1% at 5 years. The core laboratory
reported one device migration at 1 year, and the sites
reported four additional migrations between 2 and 5 years;
1 required a secondary procedure. A total of 28 new and
persistent type I and III endoleaks were reported through 5
years; 9 required a secondary procedure.
Conclusion: The Talent eLPS Pivotal trial showed
excellent safety and effectiveness compared with open sur-
gical repair at 1 year. Durability and effectiveness of EVAR
is maintained to 5 years. ARM at 5 years was low in a
population that included patients with more challenging
anatomic characteristics than other AAA IDE trials.
Commentary LB3: These investigators report the
5-year follow-up results of the initial Medtronic Talent
AAA IDE Study and compare outcomes with those from
the SVS Lifeline Registry open surgical controls. The ana-
tomic inclusion criteria allowed for less optimal aortic anat-
omy (neck length5 mm) for EVAR compared with other
AAA IDE trials, with 34% of patients having proximal neck
lengths 15 mm and diameters 28 mm.
Despite this challenging anatomy, there were high rates
of freedom from all-cause mortality (68.8%), freedom from
ARM (96.5%), and low rates of endoleaks, graft migration,
secondary procedures, and conversion to open repair at 5
years. These 5-year results compare favorably with those of
other devices. The investigators have continued to add
more patients to the VITALITY Post-Approval US Study
to look at the longer-term safety and effectiveness.
LB4. Intermediate Results of a US Multicenter Trial
of Fenestrated Endograft Repair for Juxtarenal
Abdominal Aortic Aneurysms. Greenberg RK,
Sternbergh WC, Makaroun M, Ohki T, Chuter T,
Bharadwaj P, et al; for the Fenestrated Investigators.
Objective: To report the intermediate-term (24-
month) outcomes of a prospective multicenter trial de-
signed to evaluate the Zenith Fenestrated AAA (abdominal
aortic aneurysm) Endovascular Graft for treating juxtarenal
AAAs.
Methods: Six centers in the United States enrolled 30
patients with juxtarenal AAAs with 50 mm diameter and
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ate the safety and preliminary effectiveness of the device,
assess the physician learning curve, refine patient selection
criteria, and develop experienced physicians. Devices were
custom-designed for each patient based on measurements
from reconstructed computed tomography (CT) data.
Follow-up included physical examinations, laboratory
studies, CT imaging, mesenteric-renal duplex ultra-
sound, and kidneys ureter and bladder radiography at
hospital discharge, at 1, 6, and 12 months, and yearly
thereafter up to 5 years.
Results: During a 1-year period, 30 patients (80%
men; mean age, 75 years; mean aneurysm size, 61.4 mm)
were enrolled in whom 77 visceral vessels were accommo-
dated by fenestrations located within the sealing segment of
the grafts. The most common design accommodated two
renal arteries and the superior mesenteric artery (66.7%).
All prostheses were implanted successfully without any
acute loss of visceral arteries. Of the 30 patients treated,
follow-up was available for 27 at 12 months and 23 at 24
months. No aneurysm-related deaths, aneurysm ruptures,
or conversions were observed through 24 months of fol-
low-up. No type I or type III endoleaks were observed at
any time. Type II endoleaks were noted in 26.1% (6 of 23)
at 12 months and in 20.0% (4 of 20) at 24 months. No
aneurysm growth 5 mm occurred. Aneurysm size de-
creased in 69.6% (16 of 23) and was stable in the remaining
patients at 24 months. Eight patients experienced evidence
of some renal event (4 renal artery stenoses, 2 renal artery
occlusions, and 2 renal infarcts), and among them, 5 un-
derwent secondary interventions. No renal failure devel-
oped requiring dialysis.
Conclusions: The placement of fenestrated endovas-
cular grafts is feasible at centers with experience in endo-
vascular aneurysm repair and renal/mesenteric stent place-
ment. The intermediate-term (24-month) results are
concordant with other studies at single centers and support
the concept that this technology is safe, effective, and
transferable across multiple centers.
Commentary LB4: The infrarenal aorta continues to
dilate after standard infrarenal endograft placement, mak-
ing the proximal seal in a short neck tenuous at best. An
endovascular solution to this problem involves moving this
attachment site cephalad to a more stable visceral aortic
segment. The price to pay for this healthier aorta is a more
complex procedure and the risk of adverse renal and visceral
artery events. Such a renal event occurred in 8 of 30 patients
in the present study, a somewhat higher rate than previous
studies. The optimal visceral artery stent has yet to be
determined.
The true value of such an approach will require
longer follow-up beyond 2 years to see how durable this
more proximal seal is, although early to midterm results
in selected patients and selected experienced surgeons
hands are encouraging. This approach appears transfer-
able to suitably experienced surgeons and is an option forhigher-risk patients with short infrarenal necks. Open
repair remains a valid alternative in lower-risk individu-
als.
LB5. Endovascular Repair Compared with Surveillance
for Patients with Small Abdominal Aortic Aneurysms.
Ouriel K, Clair DG, Kent KC, Zarins CK; for the Positive
Impact of Endovascular Options for Treating Aneurysms
Early (PIVOTAL) Investigators.
Objective: Although repair of large abdominal aortic
aneurysms is well accepted, randomized clinical trials have
failed to demonstrate benefit for early surgical repair of
small aneurysms over surveillance. Endovascular repair has
been demonstrated to be safer than open surgical repair in
patients with large aneurysms, prompting a randomized
trial of early endovascular repair vs surveillance in patients
with small aneurysms.
Methods: Patients with 4- to 5-cm abdominal aortic
aneurysms were randomized to early endovascular repair or
ultrasound surveillance. Rupture or aneurysm-related
death and overall death were compared in the two groups
during a mean follow-up of 20  12 (SD) months.
Results: Of 728 patients with small aneurysms (di-
ameter, 4.5  0.3 cm) 366 were randomly assigned to
early endovascular repair and or 362 to ultrasound sur-
veillance. The mean age was 71  8 years, and approxi-
mately 13% were women. After mean follow up of 20 
12 months (range, 0-41 months), there were 15 deaths
in each group (4.1%), and the unadjusted hazard ratio
for mortality after early endovascular repair was 1.01
(95% confidence limit [CL], 0.49, 2.07; P  .98). An-
eurysm rupture or aneurysm-related death occurred in
two patients in each group (0.6%). The unadjusted haz-
ard ratio was 0.99 (95% CL, 0.14, 7.06; P  .99) for
early endovascular repair.
Conclusions: Early treatment with endovascular re-
pair and vigorous ultrasound surveillance both appear to be
safe alternatives for patients with small abdominal aneu-
rysms, protecting the patient from rupture or aneurysm-
related death for up to 3 years.
Commentary LB5: Randomized studies have failed
to show an advantage to early open repair over surveillance
of small aneurysms. The investigators postulated that there
might be an advantage to early endovascular repair with its
lower risk of perioperative mortality. Because the enroll-
ment rates were slower than expected, the investigators
performed a futility analysis of early results and decided to
stop enrollment in November 2008, with 728 of the orig-
inal 1050 patients recruited.
With no difference in aneurysm-related mortality, rup-
ture, or survival, there does not appear to be an advantage
to early endovascular repair over surveillance. During the
3-year follow-up period, however, 31% of the surveillance
group underwent aneurysm repair, whereas 12% of the
repair arm did not. This is important to keep in mind as the
study follow-up is completed.
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Mortality in Stable Peripheral Arterial Disease: A
Substudy of the Iron and Atherosclerosis (FeAST)
Trial. DePalma RG, Hayes VW, Chow BK, Shamayeva
G, May PE, Zacharski LR.
Objective: This research aimed to define relationships
between iron storage and inflammatory biomarkers in co-
hort of 100 participants at the Veterans Affairs (VA) Sierra
Nevada Health Care System (SNHCS) with peripheral
arterial disease (PAD). A prospective randomized, single,
blind clinical trial entering 1277 cancer-free patients with
advanced peripheral arterial disease (PAD) from 24 partic-
ipating VA hospitals (VA Cooperative Study #410, The
Iron and Atherosclerosis Study [FeAST]) tested the hy-
pothesis that iron in excess of physiologic requirements
contributes to atherosclerosis. Patients were randomized to
calibrated iron reduction by graded phlebotomy or control
groups. The primary outcome was all-cause mortality, and
the secondary outcome was death plus nonfatal myocardial
infarction and stroke. Data on cardiovascular disease
(CVD) outcomes and on the occurrence of new cancer
diagnoses and cancer-specific death were collected prospec-
tively and analyzed by intent-to-treat. In the main study
population, iron reduction resulted in a significant age-
related improvement in primary and secondary CVD as well
as cancer death. Levels of ferritin correlated with inflamma-
tory biomarkers during the SNHCS substudy.
Methods: Approval was obtained to measure the cy-
tokines interleukin (IL) 6, tumor necrosis factor- recep-
tors 1 and 2, IL-2, IL-10, and high-sensitivity C-reactive
protein (hs CRP) at entry and at 6-monthly follow-up
intervals on 100 participants monitored during the 6-year
study period. We explored relationships between iron sta-
tus (ferritin levels) and inflammatory markers at entry and
during follow-up in this subset of FeAST participants.
Results: The main and substudy participants were an
average age of 67 9 years at entry. Clinical and laboratory
parameters at entry were comparable in the 51 participants
randomized to iron reduction and 49 controls. At baseline,
53 entrants receiving statins trended lower mean ferritin
levels (114.06 ng/mL; 95% confidence interval [CI],
93.43-134.69) compared with 47 participants not receiv-
ing statins (127.6 ng/mL; 95% CI, 103.21-152.02; P 
NS). During the study interval, 31 additional participants
started taking statins. Longitudinal analysis using all fol-
low-up data showed that after adjusting for the phlebotomy
treatment effect, statins had a significant effect on the
reduction of ferritin (29.78 ng/mL), with a Cohen effect
size of 0.47 (t  2.33, P  .0123). Mean follow-up
ferritin levels were higher in 23 participants who died
compared with the 77 survivors (132 vs 86.3 ng/mL; P 
.0050). Mean follow-up IL-6 levels were higher in the 23
participants who died compared with the 77 survivors (P
.03). Pearson correlations showed significant relationships
between levels of ferritin and IL-6 (P  .002) and hsCRP
(P  .04).Conclusion: These data support the hypothesis that
iron-catalyzed oxidative stress may contribute to inflamma-
tion in patients with PAD.
Commentary LB6: Important results from this VA
study include the finding that higher ferritin levels and
inflammatory biomarkers are associated with cardiovascular
death and that statins reduced these ferritin levels, indepen-
dent from the effects of phlebotomy. The investigators
propose additional trials of iron reduction in younger pa-
tients and, in the mean time, continued statin use and
consideration of iron reduction in those at risk of cardio-
vascular events.
LB7. Objective Performance Goals (OPG) for the
Treatment of Critical Limb Ischemia (CLI): Importance
of Risk Stratification in Clinical Trial Design and
Reporting. Conte MS, Geraghty PJ, Bradbury AW,
Hevelone ND, Moneta GL, Nehler MR, et al.
Objectives: The evaluation of new devices targeting
the critical limb ischemia (CLI) population presents major
challenges in clinical trial design. We sought to develop
objective performance goals (OPG) and to define appropri-
ate outcome measures for CLI trials.
Methods: We pooled line-item data from three pro-
spective multicenter trials of open surgical revascularization
for CLI: Edifoligide for the Prevention of Infrainguinal
Vein Graft Failure (PREVENT-III), Circulase II, and By-
pass versus Angioplasty in Severe Ischemia of the Leg
(BASIL). We included data for patients undergoing surgi-
cal bypass using autogenous vein. Test-drug treatment, use
of prosthetic, and end-stage renal disease patients were
excluded. End points included major adverse cardiac events
(MACE), death, amputation, and reintervention. We de-
fined a major adverse limb event (MALE) as consisting of
amputation or a major reintervention (new bypass graft,
thrombolysis, jump or interposition graft revision). Periop-
erative (30-day) death was combined with any MALE to
generate the primary efficacy end point MALE(). Other
composite end points included amputation-free survival.
Event rates were calculated by Kaplan-Meier analysis. Uni-
variate and multivariate analyses defined risk criteria based
on patient characteristics, anatomy, and conduit quality.
Results: Data from 838 surgical cases from the three
trials were included. Perioperative MACE was 6.2%, in-
cluding 2.7% mortality. The combination of age80 years
and tissue loss (80) was associated with a 3.1-fold in-
creased risk of 30-day MACE and notably inferior out-
comes for all end points that included death as an event
(Table). Infrapopliteal outflow anatomy and the use of a
high-risk conduit (nonsaphenous, spliced, or small-caliber
vein) were also significant outcome stratifiers, particularly
for the limb-related end points.
Conclusions: Patient age (80 years), presence of
tissue loss, infrapopliteal disease, and lack of adequate
saphenous vein are useful stratification criteria for clinical
trial designs in the CLI population. MALE is a clinically
relevant efficacy measure for limb revascularization, distinct
from amputation-free survival. These data were used to
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Commentary LB7: Any studies describing critical
limb ischemia (CLI) are plagued with inconsistent defini-
tions and use of outcome measures and reporting stan-
dards. In this Society for Vascular Surgery initiative, the
authors attempt to clarify some of these issues regarding
CLI outcome measures by pooling data from three recent
trials. Elderly patients with tissue loss were more apt to
experience a cardiac event or die, and suboptimal conduits
and tibial disease were associated with more frequent limb-
related events. These findings are not surprising.
The main benefit of this study is the justification of a
clinically relevant outcome measure, major adverse limb
event (MALE), distinct from amputation-free survival. This
allows for the setting of performance goals and use of such
measures in further surgical revascularization and interven-
tional CLI studies. The investigators propose an assessment
schedule and a set of periprocedural and longer-term end
points to be used in future CLI trials.
LB8. Safety and Efficacy of HGF Plasmid Gene
Therapy on Limb Perfusion and Wound Healing in
Patients with Ischemic Lower Extremity Ulceration:
Results of the HGF-0205 Trial. Powell RJ, Marrot P,
Annex BH.
Objectives: We have previously reported the results of
a dose-finding phase II trial showing that HGF angiogenic
gene therapy can increase transcutaneous partial pressure of
oxygen (TcPO2) compared with placebo in patients with
critical limb ischemia (CLI). This randomized, placebo-
controlled, multicenter trial further assessed the safety and
clinical efficacy of a modified HGF gene delivery technique
in patients with CLI and no revascularization options.
Methods: Patients with tissue loss received three sets
of eight intramuscular injections every 2 weeks of HGF
plasmid under duplex ultrasound guidance. Injection loca-
Table. Study outcomes
Outcome by group 3 months
Complete ulcer healing, %
HGF 6%
Placebo 0%
Difference from baseline
Visual analog pain score (cm)
HGF 1.05  0.8
Placebo 0.5  0.3
Toe pressure
HGF 6.8  5.8
Placebo 25  2.0
Toe-brachial index
HGF 0.04  0.04
Placebo 0.14  0.02tions were individualized for each patient based on arterio-graphically defined vascular anatomy. The primary safety
end point was incidence of adverse events or serious adverse
events. Clinical end points included change from baseline
in toe-brachial index (TBI), rest pain assessment by a
10-cm visual analog scale, as well as wound healing, ampu-
tation, and survival at 3 and 6 months.
Results: The randomization ratio was 4:1 HGF (n 
21) vs placebo (n  6). Mean age was 76  2 years, 56%
were men, and 59% were diabetic. There was no difference
in demographics between groups. There was no difference
in adverse events or serious adverse events, which consisted
mostly of transient injection site discomfort, worsening of
CLI, and intercurrent illnesses. Change in TBI and rest
pain significantly improved from baseline at 6 months in
the HGF-treated group compared with placebo (Table).
Complete ulcer healing at 12 months occurred in 31% of
the HGF group and in 0% of the placebo group (P  .21).
There was no difference in amputation (HGF, 19% vs
placebo, 20%) or mortality (HGF, 19% vs placebo, 13%)
between groups.
Conclusions: HGF gene therapy using a patient vas-
cular anatomy specific delivery technique appears safe,
maintained limb perfusion, and decreased rest pain in pa-
tients with CLI compared with placebo. A larger study to
assess the efficacy of this therapy on more clinically relevant
end points is warranted.
Commentary LB8: The investigators report promis-
ing results after HGF angiogenic gene therapy, with im-
provements in toe brachial indices, pain control, and ulcer
healing in a small cohort (n  21) of patients with tissue
loss compared with placebo (n  6). Amputation rates did
not differ. Injection sites in the ischemic extremity were
individualized and guided based on the anatomic distribu-
tion of the occlusive disease. As larger studies are performed
to validate these results, it will be interesting to correlate
revascularization and limb salvage outcomes with the local
P 6 months P
1.0 19% .55
0%
.20 1.91  1.3 .04
0.6  0.2
.02 5.8  6.9 .07
29.8  8.1
.057 0.05  0.05 .047
0.17  0.04effects of these injections on the peripheral vasculature.
